Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, 430071, P.R. China.
Signal Transduct Target Ther. 2022 Jun 25;7(1):199. doi: 10.1038/s41392-022-01056-1.
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative opportunistic pathogen that infects patients with cystic fibrosis, burn wounds, immunodeficiency, chronic obstructive pulmonary disorder (COPD), cancer, and severe infection requiring ventilation, such as COVID-19. P. aeruginosa is also a widely-used model bacterium for all biological areas. In addition to continued, intense efforts in understanding bacterial pathogenesis of P. aeruginosa including virulence factors (LPS, quorum sensing, two-component systems, 6 type secretion systems, outer membrane vesicles (OMVs), CRISPR-Cas and their regulation), rapid progress has been made in further studying host-pathogen interaction, particularly host immune networks involving autophagy, inflammasome, non-coding RNAs, cGAS, etc. Furthermore, numerous technologic advances, such as bioinformatics, metabolomics, scRNA-seq, nanoparticles, drug screening, and phage therapy, have been used to improve our understanding of P. aeruginosa pathogenesis and host defense. Nevertheless, much remains to be uncovered about interactions between P. aeruginosa and host immune responses, including mechanisms of drug resistance by known or unannotated bacterial virulence factors as well as mammalian cell signaling pathways. The widespread use of antibiotics and the slow development of effective antimicrobials present daunting challenges and necessitate new theoretical and practical platforms to screen and develop mechanism-tested novel drugs to treat intractable infections, especially those caused by multi-drug resistance strains. Benefited from has advancing in research tools and technology, dissecting this pathogen's feature has entered into molecular and mechanistic details as well as dynamic and holistic views. Herein, we comprehensively review the progress and discuss the current status of P. aeruginosa biophysical traits, behaviors, virulence factors, invasive regulators, and host defense patterns against its infection, which point out new directions for future investigation and add to the design of novel and/or alternative therapeutics to combat this clinically significant pathogen.
铜绿假单胞菌(P. aeruginosa)是一种革兰氏阴性机会致病菌,可感染囊性纤维化、烧伤、免疫缺陷、慢性阻塞性肺疾病(COPD)、癌症以及需要通气的严重感染患者,如 COVID-19。铜绿假单胞菌也是所有生物领域广泛使用的模式细菌。除了持续、深入地研究铜绿假单胞菌的细菌发病机制(包括脂多糖、群体感应、双组分系统、6 型分泌系统、外膜囊泡(OMVs)、CRISPR-Cas 及其调控)外,宿主-病原体相互作用的研究也取得了快速进展,特别是涉及自噬、炎性体、非编码 RNA、cGAS 等的宿主免疫网络。此外,许多技术进步,如生物信息学、代谢组学、单细胞 RNA-seq、纳米颗粒、药物筛选和噬菌体治疗,已被用于提高我们对铜绿假单胞菌发病机制和宿主防御的理解。然而,铜绿假单胞菌与宿主免疫反应之间的相互作用仍有许多有待揭示,包括已知或未注释的细菌毒力因子以及哺乳动物细胞信号通路的耐药机制。抗生素的广泛使用和有效抗菌药物的缓慢发展带来了严峻的挑战,需要新的理论和实践平台来筛选和开发经过机制验证的新型药物,以治疗难治性感染,特别是由多药耐药株引起的感染。得益于研究工具和技术的进步,对这种病原体的特征的研究已经进入了分子和机制细节以及动态和整体观点。在此,我们全面综述了铜绿假单胞菌生物物理特性、行为、毒力因子、侵袭调控因子以及宿主防御模式的研究进展,并讨论了其感染的现状,为未来的研究指明了新的方向,并为设计针对这种具有临床重要性的病原体的新型或替代疗法提供了依据。